Diabetes

Analyzing factors associated with continuing care participation in patients with diabetes and with interrupted participation by patients enrolled in a diabetes pay-for-performance program.

The findings on salt intake were timed to coincide with the release of the 2015 Dietary Guidelines for Americans.

Last February, the Dietary Guidelines Advisory Committee trumpeted its recommendations to promote sustainability and curtail consumption of red and processed meat. After a year of intense lobbying, neither item made survived the final cut in the 2015 report released today.

Disappointing sales were blamed on prior authorization, the FDA label restrictions, and the need for spirometry before doctors could write prescriptions.

The trials would involve the University of Virginia School of Medicine and Harvard's Paulson School of Engineering and Applied Science

Study finds kids in an urban district picked healthy food after changes to the school lunch program, but it doesn't measure whether they ate it.

The research has important implications for finding a potential cure for type 1 diabetes.

Studies that provided updates on new drug trials, sessions on value-based care, and the cost of healthcare, were most popular among readers of The American Journal of Managed Care.

Bariatric surgery is becoming a more popular method to address obesity, so physicians and surgeons should be more aware of how time of year affects outcomes.

Stories about therapy, led by updates on Afrezza, were most popular with readers interested in diabetes care.

The prior CEO of MannKind attributed slow sales of Afrezza in part to slow reimbursement from insurers.

A new study has provided the first strong evidence that warfarin can interact adversely with anti-diabetes drugs and cause serious hypoglycemic events.

It appears Sanofi will use a priority review voucher to catch up in the process to Novo Nordisk, which submitted an NDA for Xultophy in late September.

The effort aims to prevent diabetes by urging Americans to get annual checkups and know 4 key numbers: BMI, blood pressure, blood sugar, and cholesterol.

The award is believed to be the largest in Indiana under the Americans with Disabilities Act for a person with diabetes.

Sessions on obesity and the role of technology in disease management will be part of the annual gathering of stakeholders, presented by The American Journal of Managed Care, April 7-8, 2016, at the Teaneck Marriott at Glenpointe in Teaneck, New Jersey.

This week in managed care, Martin Shkreli, CEO of Turing Pharmaceuticals was arrested on charges of fraud; new research find that drug costs continue to take up a larger share of healthcare spending; and 3 healthcare experts take a look at how to fix the 340B drug pricing program.

Multiple studies have shown improved outcomes by placing pharmacists into diabetes management roles. With a chronic condition such as diabetes, which impacts 29 million Americans, that’s welcome news. As the number of people with diabetes continues to escalate, we are faced with not only a physician shortage, but a provider shortage. We need to embrace the role of healthcare professionals like pharmacists and further expand their impact through the use of digital health technologies, which encourage patient engagement and extend care.

In updates from FDA, a copycat insulin is approved and final restrictions are lifted on a one-time blockbuster diabetes drug that all but disappeared from the market.

The new drug application says the insulin will be faster-acting, but it does not say just how fast.

The study used Medicare data to identify patients who took both warfarin and 1 of 2 common sulfonylureas.

The data showed strong associations between certain behavioral factors and likelihood of childhood obesity, such as late or irregular bedtimes and a mother's smoking habit during pregnancy.

The year 2014 was critical in the trajectory of prescription drug costs, as many therapies came off patent and health plans took steps to insulate themselves from the effects of the Affordable Care Act.

Disease management programs for diabetes care based on bundled payment did not slow down the cost growth. Multimorbid adult patients with diabetes had largest cost growth.

The battle for presence in health plans and on formularies between the two cholesterol-fighting drugs has been fierce.